Role of ions in Prolactin release.
To study the role of ions in the release of Prolactin (PRL), several experiments were performed utilizing dispersed pituitary cells obtained from adult, female Sprague-Dawley rats. All tests were done after a culture period of 5 days in multiwell Petri plates at 3 x 10 5 cells per well. Culture medium was Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% horse serum, 2.5% fetal calf serum, non-essential amino-acids and antibiotics. PRL secretion was measured by specific RIA after 4 h of test incubation in various media at 37 0 in a CO 2/air incubator. Basal PRL secretion in DMEM (154±12 ng/ml) was drastically reduced in a hypoosmolar, sodium deprived medium (48±4 ng/ml) , remained low when NaCl was replaced by isoosmolar concentrations of glucose (33±2 ng/ml), and was restored by the addition of either sodium or choline 110 mH. When DA 10-11M was added to the medium with sodium, an 83% increment of PRL secretion was observed, while the neurotransmitter was completely inactive in absence of NaCl. DA 5 x 10-6M strongly inhibited PRL release in the presence of sodium but was inactive either in the absence of the ion or when the ion channel was blocked by tetrodotoxin (TTX). Baseline and DA-stimulated PRL release were also strongly inhibited by the addition to the medium of either Co++ (a calcium channel blocker) or TTX. These results indicate that a normal ionic charge in the medium is essential for baseline PRL secretion, while both sodium and calcium ions Between 1953 and 1980 71 cases (M43:F28) of craniopharyngioma were treated either by cyst aspiration with DXT or tumour resection: DXT. Of the 13 cases treated by aspiration, only one had diabetes insipidus and 2 reqUired thyroxine treatment. However, at least 5 cases are known to have died, 4 as a result of tumour recurrence. There was a much higher incidence of pituitary deficits in the 58 cases treated by tumour resection. 4b/58 had DI, 33/42 GH deficiency, 23/35 ACTH deficiency, 16/18 gonadotrophin deficiency, and 14/19 TSH deficiency. While only one patient died from tumour recurrence, at least 13 died because of endocrine deficits: 6 because of distur~ed post-operative fluid balance and 7 following relatively minor intercurrent illness. In addition, 11 cases reqUired emergency admission to hospital because of hypoglycaemia (8 cases)t circulatory failure (1 case) or water overload (2 cases). R. POHAREDE~P. CZERNICHOW and R. RAPPAPORT.
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Hopital 26 patients (6 familial) were investigated, with a followup of 4-20 yrs (x= 12.5 yrs) after onset of polyuria. Pneumoencephalography (n= 27) and/or CT scan (n= 11) were normal.
GH deficiency was present in 10/26 cases. Recovery, not related to puberty in all cases, was observed in 5 patients.
TSH response to TRF (n= 17) was deficient (n= 3) or of the hypothalamic type (n= 4). Puberty was normal in 17 cases, and abnormal in 2 cases (respectively precocious and slowly progressing). GH deficiency was isolated in 5 cases or associated with ACTH +TSH (n= 1), TSH (n= I), ACTH (n= 3) abnormalities.
In conclusion : long term observation is necessary to ascerta1n the d1agnosis of idiopathic 01. Anterior pituitary deficiency may be associated, without any evidence of tumor. GH deficiency may be transient. These findings suggest that hypothalamic disturbances leading to idiopathic 01 involve more that the hypothalamic posterior pituitary system itself. I!LInan growth honrone (IIGI) is ocmronly administrated by 10m. injections. '1lle high p.Jrity of the present IIGI preparations makes s ,c , administration an attractive alternative enabling se1f-administration. In this study tm.e courses of p1asna IIGI after s ,c and 1om.injections of highly purIfIed IIGI (Nanomon R) are described and carpared to the diurnal plasma IIGI profile in eight normal, children (11-14 years). Seven patients suffering fran idiopathic IIGI-deficient dwarfism (age 10-19 years) received 10m. and a,c, injection of IIGI in the IIOming (4IU/rn2) in randan order with an interval of one~. I.m. injections lead to a peak HGl concentration at 2 lnJrs (mean 204,range 135-475 ng/rnl) with a return to baseline 8-10 lnJrs after injection.Corresp:>ooing1y HGl concentration peaked at 4 hrs (mean 38,range 15-68 ng/rnl)after s.c. injection and retw:ned to baseline about 18 hours after injection. In a subsecruent study on slmilar patients (n=7,age 10-19 years) IIGI (2IU/rn 2) was injected s ,c, in the even1ng.HGl concentration peaked at 5 hours (mean 17,range 7-28 ng/rnl) and returned to baseline 14 bours after injection.'rile results in:1icate that absorption fran an 10m. depot; is far too short; to give a FhYsiologica1 diurnal profile of IIGI in plasma -even by daily administration. 1boeTer, daily s ,c, injection will,if given in the even1ng,lmitate mIInal nocturnal IIGI profile. RUTH ILLIG,M. ZACHMANN and A. PRADER 
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Dept. of Pediatrics, University of Zurich, Switzerland "A-type" isolated growth honnone deficiency (IGHD). In 1970, we p..sented the "A-type" of autosomal receuive IGHD characterized by early and severe growth retordation, typical face with vaulted farehead, a strong metabolic and grewth relpOnse to exogenous hGH, and a tendency to fann high GH antibodies which abol ish this effect.
Recent events prompt us to report on these patients again: 1) Philipps et al (abstr.Ped.Res. 1981) carried out restriction endonuclease studies in our original family A, yielding abnonnal DNA patterns of the GH genes. In other families with IGHD, they faund a nonnal pattern. 2) One of our female patients of the same family (26 years, 118 em) gave birth to a healthy girl (GA.co weeks, 2370 g, 43 em). GH antibodies were found not only in the mother (12 years after the end of hGH~) but also in the newborn. Five months later, no mo.. antibodies were detectable. 3) In another family we succeeded far the first time to treat a 5 year-old boy with hGH over a period of 1.5 years without the appearance of HG antibodies so far. This is in contrast to his 10 year-old brother previously treated with a diffe..nt hGH preparation who developped high tit.., growth-inhibiting GH antibodies. It appears that certain hGH preparations are tolerated by th_ patients who presumobly suffer from a prenatal GH deficiency which may cause a lack of immunotolerance for hGH. Supported by the Swiu Notional Science Foundation Grant No. 3.901.077
